Last reviewed · How we verify
A Randomized, Parallel Group, Three-Arm Study To Evaluate Treatment With A Combination Of Pegvisomant Plus Sandostatin Lar, Pegvisomant (Alone), And Sandostatin Lar (Alone) In Patients With Acromegaly
The purpose of this study is to compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.
Details
| Lead sponsor | Pfizer |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 75 |
| Start date | 2003-10 |
| Completion | 2006-05 |
Conditions
- Acromegaly
Interventions
- Pegvisomant/ Sandostatin LAR
- Sandostatin LAR
- Pegvisomant
Primary outcomes
- Number of subjects experiencing treatment-emergent adverse events across the duration fo the study
Countries
United States, Australia, Brazil, Canada, France, Germany, Italy, Mexico, Netherlands, Norway, Spain, United Kingdom